UNSPSC 51372129: Oxymorphone hydrochloride

This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H19NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Y2EI94NBC, chemically known as 4,5alpha-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one hydrochloride but more generally known as oxymorphone hydrochloride, which bears US NIH Compound Identifier 5359390. European Medicines Agency schedules Oxymorphone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03591MIG.

UNSPSC 51372129 Oxymorphone hydrochloride is a Commodity code that encompasses pharmaceutical products procured by state and local health agencies, primarily for community health and pharmacy benefit programs. State and local governments buy controlled and non-controlled pharmaceuticals under this code to support addiction-treatment initiatives, pharmacy benefit management, and community health delivery. The mix of issuing bodies includes county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Procurement vehicles range from traditional competitive bidding (IFB) to exploratory requests for information (RFI) and cooperative purchasing RFPs, reflecting both direct procurement and indirect contracting through wholesaler networks.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released an IFB (IFB60459723LAS, response deadline July 26, 2023) to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for delivery to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state pharmacy benefit program and manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802, response deadline March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) across participating state and local government facilities, including Oregon. Price competitiveness was weighted at 75 percent in the MMCAP evaluation, with vendors required to maintain relationships with at least two of the three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements.